Capital Fund Management S.A. Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Capital Fund Management S.A. decreased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 83.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,327 shares of the biotechnology company's stock after selling 298,288 shares during the period. Capital Fund Management S.A.'s holdings in BioCryst Pharmaceuticals were worth $446,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $46,000. R Squared Ltd purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $48,000. KBC Group NV increased its position in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $80,000. Finally, Quantinno Capital Management LP bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $82,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

BCRX stock traded up $0.29 on Tuesday, reaching $7.82. The company's stock had a trading volume of 4,264,157 shares, compared to its average volume of 2,809,164. The firm has a market cap of $1.63 billion, a PE ratio of -12.82 and a beta of 1.75. The business has a fifty day simple moving average of $7.77 and a two-hundred day simple moving average of $7.74. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. During the same period last year, the company posted $0.28 earnings per share. The company's revenue for the quarter was up 40.8% on a year-over-year basis. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Royal Bank of Canada reiterated an "outperform" rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Wedbush started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective for the company. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.